Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Executive Summary
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?
You may also be interested in...
Q1 Was Slow For Deals, But That Could Change With One Big Transaction – PwC
Life science deal-making declined by volume during the first quarter, but aggregate value was up. Looking ahead, PwC sees an ideal environment for major deals – if something like Takeda/Shire sparks a trend.
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.